iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia
Jerry Hu, M.D. appointed to Board of Directors February 05, 2025 06:00 AM Eastern Standard Time SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company advancing IVMED-85 for the treatment of pediatric myopia,…